UK based clinical stage stem cell business, ReNeuron is moving ahead with its programme of clinical trials. The CFO, Michael Hunt, tells Proactiveinvestors the company is expecting initial results from its phase 2 trials of CTX for stroke victims by the end of 2015 with further data from that trial in the early part of 2016.
The company is also expecting the CLI programme to move out of phase I and into phase II in the second half of this year, and the phase I/II retinitis pigmentosa trial is expected to commence in the US this year.
ReNeuron raised £25 million in 2013 and has the funding in place to complete all of these clinical trials. It is also opening a world class cell manufacturing facility in South Wales.